Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE® multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate’s ANKETTM proprietary platform Selection of IPH6401/SAR’514 triggers a €3M milestone payment to Innate MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) … [Read more…]
